Anti-inflammatory and anti-fibrotic profile of fish oil emulsions used in parenteral nutrition-associated liver disease

PLoS ONE

Volumn 9, Issue 12, 2014, Pages

  Pastor Clerigues, Alfonso ^a   Marti Bonmati, Ezequiel ^a   Milara, Javier ^a,c   Almudever, Patricia ^b   Cortijo, Julio ^a,b,c  

^a HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^b UNIVERSITY OF VALENCIA   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CLINOLEIC; FISH OIL; GELATINASE B; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; LIPID EMULSION; LIPOFUNDIN; LIPOPOLYSACCHARIDE; OMEGAVEN; SMOFLIPID; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANTIINFLAMMATORY AGENT; OMEGA 6 FATTY ACID; SOYBEAN OIL;

ADULT; AGED; ANTI LIVER FIBROSIS ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL CULTURE; CELL STIMULATION; CLINICAL ARTICLE; DISEASE ASSOCIATION; DRUG ACTIVITY; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LIVER BIOPSY; LIVER DISEASE; LIVER FIBROSIS; LIVER PROTECTION; MALE; MONOCYTE; MONOTHERAPY; PARENTERAL NUTRITION; PARENTERAL NUTRITION ASSOCIATED LIVER DISEASE; PROTEIN BLOOD LEVEL; SUPERNATANT; TREATMENT RESPONSE; ADVERSE EFFECTS; CELL CULTURE TECHNIQUE; CICATRIX; HOME PARENTERAL NUTRITION; LIVER DISEASES; MIDDLE AGED; PROCEDURES;

GLYCINE MAX;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS; CELL CULTURE TECHNIQUES; CICATRIX; EPITHELIAL-MESENCHYMAL TRANSITION; FAT EMULSIONS, INTRAVENOUS; FATTY ACIDS, OMEGA-6; FEMALE; FISH OILS; HUMANS; LIVER DISEASES; MALE; MIDDLE AGED; PARENTERAL NUTRITION, HOME; SOYBEAN OIL;

EID: 84917675438     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0115404     Document Type: Article

References (42)

1. Dudrick SJ (2003) Early developments and clinical applications of total parenteral nutrition. JPEN J Parenter Enteral Nutr 27: 291-299.
2. Carter BA, Karpen SJ (2007) Intestinal failure-associated liver disease: management and treatment strategies past, present, and future. Semin Liver Dis 27: 251-258.
3. Kelly DA (1998) Liver complications of pediatric parenteral nutrition-epidemiology. Nutrition 14: 153-157.
4. Chan S, McCowen KC, Bistrian BR, Thibault A, Keane-Ellison M, et al. (1999) Incidence, prognosis, and etiology of end-stage liver disease in patients receiving home total parenteral nutrition. Surgery 126: 28-34.
5. Clayton PT, Bowron A, Mills KA, Massoud A, Casteels M, et al. (1993) Phytosterolemia in children with parenteral nutrition-associated cholestatic liver disease. Gastroenterology 105: 1806-1813.
6. Goulet O, Joly F, Corriol O, Colomb-Jung V (2009) Some new insights in intestinal failure-associated liver disease. Curr Opin Organ Transplant 14: 256-261.
7. Sala-Vila A, Barbosa VM, Calder PC (2007) Olive oil in parenteral nutrition. Curr Opin Clin Nutr Metab Care 10: 165-174.
8. Lee S, Gura KM, Puder M (2007) Omega-3 fatty acids and liver disease. Hepatology 45: 841-845.
9. Chen WJ, Yeh SL (2003) Effects of fish oil in parenteral nutrition. Nutrition 19: 275-279.
10. Le HD, de Meijer VE, Zurakowski D, Meisel JA, Gura KM, et al. (2010) Parenteral fish oil as monotherapy improves lipid profiles in children with parenteral nutrition-associated liver disease. JPEN J Parenter Enteral Nutr 34: 477-484.
11. Cavicchi M, Beau P, Crenn P, Degott C, Messing B (2000) Prevalence of liver disease and contributing factors in patients receiving home parenteral nutrition for permanent intestinal failure. Ann Intern Med 132: 525-532.
12. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, et al. (2005) Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41: 1313-1321.
13. Puiggros C, Sanchez J, Chacon P, Sabin P, Rosello J, et al. (2009) Evolution of lipid profile, liver function, and pattern of plasma fatty acids according to the type of lipid emulsion administered in parenteral nutrition in the early postoperative period after digestive surgery. JPEN J Parenter Enteral Nutr 33: 501-512.
14. Galbois A, Thabut D, Tazi KA, Rudler M, Mohammadi MS, et al. (2009) Ex vivo effects of high-density lipoprotein exposure on the lipopolysaccharide-induced inflammatory response in patients with severe cirrhosis. Hepatology 49: 175-184.
15. Fermino ML, Polli CD, Toledo KA, Liu FT, Hsu DK, et al. (2011) LPS-induced galectin-3 oligomerization results in enhancement of neutrophil activation. PLoS One 6: e26004.
16. Strandberg K, Blidberg K, Sahlander K, Palmberg L, Larsson K (2010) Effect of formoterol and budesonide on chemokine release, chemokine receptor expression and chemotaxis in human neutrophils. Pulm Pharmacol Ther 23: 316-323.
17. Suri S, Taylor MA, Verity A, Tribolo S, Needs PW, et al. (2008) A comparative study of the effects of quercetin and its glucuronide and sulfate metabolites on human neutrophil function in vitro. Biochem Pharmacol 76: 645-653.
18. Xue ZF, Wu XM, Liu M (2013) Hepatic regeneration and the epithelial to mesenchymal transition. World J Gastroenterol 19: 1380-1386.
19. Lamouille S, Xu J, Derynck R (2014) Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol 15: 178-196.
20. Burns DL, Gill BM (2013) Reversal of parenteral nutrition-associated liver disease with a fish oil-based lipid emulsion (Omegaven) in an adult dependent on home parenteral nutrition. JPEN J Parenter Enteral Nutr 37: 274-280.
21. Venecourt-Jackson E, Hill SJ, Walmsley RS (2013) Successful treatment of parenteral nutritionassociated liver disease in an adult by use of a fish oil-based lipid source. Nutrition 29: 356-358.
22. Xu Z, Li Y, Wang J, Wu B, Li J (2012) Effect of omega-3 polyunsaturated fatty acids to reverse biopsyproven parenteral nutrition-associated liver disease in adults. Clin Nutr 31: 217-223.
23. Mercer DF, Hobson BD, Fischer RT, Talmon GA, Perry DA, et al. (2013) Hepatic fibrosis persists and progresses despite biochemical improvement in children treated with intravenous fish oil emulsion. J Pediatr Gastroenterol Nutr 56: 364-369.
24. Soden JS, Lovell MA, Brown K, Partrick DA, Sokol RJ (2010) Failure of resolution of portal fibrosis during omega-3 fatty acid lipid emulsion therapy in two patients with irreversible intestinal failure. J Pediatr 156: 327-331.
25. Vanek VW, Seidner DL, Allen P, Bistrian B, Collier S, et al. (2012) A.S.P.E.N. position paper: Clinical role for alternative intravenous fat emulsions. Nutr Clin Pract 27: 150-192.
26. Leber B, Mayrhauser U, Rybczynski M, Stadlbauer V (2009) Innate immune dysfunction in acute and chronic liver disease. Wien Klin Wochenschr 121: 732-744.
27. Karlmark KR, Weiskirchen R, Zimmermann HW, Gassler N, Ginhoux F, et al. (2009) Hepatic recruitment of the inflammatory Gr1+ monocyte subset upon liver injury promotes hepatic fibrosis. Hepatology 50: 261-274.
28. Braunersreuther V, Viviani GL, Mach F, Montecucco F (2012) Role of cytokines and chemokines in non-alcoholic fatty liver disease. World J Gastroenterol 18: 727-735.
29. Hasegawa T, Yoneda M, Nakamura K, Makino I, Terano A (2001) Plasma transforming growth factorbeta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study. Aliment Pharmacol Ther 15: 1667-1672.
30. Sitia G, Isogawa M, Iannacone M, Campbell IL, Chisari FV, et al. (2004) MMPs are required for recruitment of antigen-nonspecific mononuclear cells into the liver by CTLs. J Clin Invest 113: 1158-1167.
31. Pellicoro A, Ramachandran P, Iredale JP, Fallowfield JA (2014) Liver fibrosis and repair: immune regulation of wound healing in a solid organ. Nat Rev Immunol 14: 181-194.
32. Segovia-Silvestre T, Reichenbach V, Fernandez-Varo G, Vassiliadis E, Barascuk N, et al. (2011) Circulating CO3-610, a degradation product of collagen III, closely reflects liver collagen and portal pressure in rats with fibrosis. Fibrogenesis Tissue Repair 4: 19.
33. Bataller R, Brenner DA (2005) Liver fibrosis. J Clin Invest 115: 209-218.
34. Mukhopadhyay P, Rajesh M, Cao Z, Horvath B, Park O, et al. (2014) Poly (ADP-ribose) polymerase-1 is a key mediator of liver inflammation and fibrosis. Hepatology 59: 1998-2009.
35. Hellerbrand C, Stefanovic B, Giordano F, Burchardt ER, Brenner DA (1999) The role of TGFbeta1 in initiating hepatic stellate cell activation in vivo. J Hepatol 30: 77-87.
36. Zeisberg M, Yang C, Martino M, Duncan MB, Rieder F, et al. (2007) Fibroblasts derive from hepatocytes in liver fibrosis via epithelial to mesenchymal transition. J Biol Chem 282: 23337-23347.
37. Wall R, Ross RP, Fitzgerald GF, Stanton C (2010) Fatty acids from fish: the anti-inflammatory potential of long-chain omega-3 fatty acids. Nutr Rev 68: 280-289.
38. Raptis DA, Limani P, Jang JH, Ungethum U, Tschuor C, et al. (2014) GPR120 on Kupffer cells mediates hepatoprotective effects of omega3-fatty acids. J Hepatol 60: 625-632.
39. Valdes F, Alvarez AM, Locascio A, Vega S, Herrera B, et al. (2002) The epithelial mesenchymal transition confers resistance to the apoptotic effects of transforming growth factor Beta in fetal rat hepatocytes. Mol Cancer Res 1: 68-78.
40. Milara J, Peiro T, Serrano A, Cortijo J (2013) Epithelial to mesenchymal transition is increased in patients with COPD and induced by cigarette smoke. Thorax 68: 410-420.
41. Wanten GJ, Calder PC (2007) Immune modulation by parenteral lipid emulsions. Am J Clin Nutr 85: 1171-1184.
42. Bianchini F, Giannoni E, Serni S, Chiarugi P, Calorini L (2012) 22: 6n-3 DHA inhibits differentiation of prostate fibroblasts into myofibroblasts and tumorigenesis. Br J Nutr 108: 2129-2137.